

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

October 30, 2002

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D. C. 20549

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 27, 2002

**IntraBiotics Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-29993**

(Commission File No.)

**94-3200380**

(IRS Employer Identification No.)

**1245 Terra Bella Avenue  
Mountain View, California 94043**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

**TABLE OF CONTENTS**

Item 5. Other Events

Item 7. Financial Statements and Exhibits

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 99.1

EXHIBIT 99.2

---

**Table of Contents**

**Item 5. Other Events**

On September 27, 2002, IntraBiotics Pharmaceuticals, Inc. (the Company ) announced preliminary results of its 509-patient Phase III clinical trial of its lead product, iseganan hydrochloride (HCl) oral solution, to treat ulcerative oral mucositis in patients undergoing high-dose chemotherapy for the treatment of cancer. These results indicated that iseganan did not meet its primary endpoint of reducing oral mucositis. As a result, the Company will cease the pursuit of severe oral mucositis as an indication for iseganan. The press release announcing the results is filed as Exhibit 99.1 hereto.

On October 14, 2002, the Company announced the implementation of a restructuring plan intended to reduce its cash operating expenses. The plan included the reduction of approximately 70% of the Company's workforce. The press release announcing the restructuring plan and the workforce reduction is filed as Exhibit 99.2 hereto.

**Item 7. Financial Statements and Exhibits**

**(c) Exhibits.**

- |      |  |
|------|--|
| 99.1 | Press Release, dated September 27, 2002, entitled IntraBiotics Announces Preliminary Results of Phase III Clinical Trial of Iseganan in Chemotherapy Patients. |
| 99.2 | Press Release, dated October 14, 2002, entitled Intrabiotics Announces Restructuring Plan  |

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IntraBiotics Pharmaceuticals, Inc.**

Dated: October 30, 2002

By: /s/ Eric H. Bjerkholt

---

Eric H. Bjerkholt  
Chief Financial Officer

2

---

**Table of Contents**

**INDEX TO EXHIBITS**

- 99.1 Press Release, dated September 27, 2002, entitled IntraBiotics Announces Preliminary Results of Phase III Clinical Trial of Iseganan in Chemotherapy Patients.
- 99.2 Press Release, dated October 14, 2002, entitled Intrabiotics Announces Restructuring Plan